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An investigation into the pathogenesis of
vulvo-vaginal candidosis
S S El-Din, M T Reynolds, H R Ashbee, R C Barton, E G V Evans
Objective: To monitor yeasts isolated from women during and between episodes of recurrent
vulvo-vaginal candidosis (VVC) to determine whether vaginal relapse or re-infection occurred.
Methods:Women presenting at the genitourinary medicine clinic with signs and symptoms of VVC
were recruited to the study (n = 121). A vaginal washing, high vaginal swab (HVS) and rectal swab
were taken and the women treated with a single 500 mg clotrimazole pessary. Women were asked to
re-attend after 1, 4, and 12 weeks, or when the VVC recurred, when vaginal washings and HVS were
repeated. Candida isolates recovered were strain typed using the Ca3 probe and their similarity
assessed. Antifungal susceptibility to fluconazole and clotrimazole were determined.
Results: Of the women recruited, 47 completed the study, either returning for four visits or suf-
fering a recurrence during the study period. Of the 22 women who experienced recurrence, the
same strain was responsible for the initial and recurrent episode in 17 women. For the remaining
five women, four had strain replacement and one had a change of species. None of the isolates
recovered from the women demonstrated resistance to either clotrimazole or fluconazole.
Conclusions: Our findings support the theory of vaginal relapse and thus may support the use
of more prolonged courses of antifungal therapy initially to increase the chances of eradication of
the yeast.
(Sex Transm Inf 2001;77:179–183)
Keywords: vaginal candidosis
Introduction
Vulvo-vaginal candidosis (VVC) is a very com-
mon condition and most women will experi-
ence at least one episode during their repro-
ductive years.1 A minority of women, however,
suVer recurrent episodes of candidosis which
can significantly aVect their quality of life and
their sexual health. While a number of factors
are probably important in the pathogenesis of
recurrent thrush, there are two main theories as
to why some women experience frequent
recurrences2:
+ Re-infection either from a sexual partner or
a reservoir of yeasts in the gut
+ Vaginal relapse due to incomplete eradica-
tion of the yeasts.
Several groups have found that in most
women with vaginal thrush, identical species
can also be isolated from the rectum.3–5
However, attempts to eradicate the carriage of
yeasts in the gut have not been shown in
controlled trials to reduce significantly the
number of symptomatic vaginal recurrences.6–9
Similarly, randomised controlled trials have
shown that the treatment of male sexual
partners with antifungals has no eVect on the
clearance and/or recurrence rate of vaginal
candida in women.10–12 Some studies have used
DNA fingerprinting methods to examine the
genetic variability of yeasts isolated from
women at successive symptomatic episodes of
candida vaginitis, but in most of them samples
were not taken between recurrences.13 14 There-
fore, it was unclear whether the yeasts were
eradicated after the initial therapy or merely
persisted without causing symptoms.
The aim of this investigation was therefore to
monitor the yeasts isolated from women not
only during but also in between recurrent epi-
sodes of VVC, using molecular strain typing, to
determine whether vaginal relapse or re-
infection occurred. The possible role of anti-
fungal resistance in VVC was also investigated.
Methods
STUDY POPULATION
A cohort of 121 premenopausal women
attending the department of genitourinary
medicine at Leeds General Infirmary with
signs and symptoms of acute VVC were
recruited into the study. Women who were less
than 16 years of age, diabetic, HIV positive, or
pregnant were excluded. Informed consent was
obtained from the patient before entry. All
patients underwent a full screen for sexually
transmitted infections, including syphilis, gon-
orrhoea, chlamydia, Trichomonas vaginalis, and
bacterial vaginosis and women with any of
these infections were excluded. The initial
diagnosis of VVC was made on clinical
grounds. The examining doctor completed a
questionnaire detailing age, history of similar
episodes, medical history, contraceptives used,
any medication taken, and symptoms and signs
at presentation. A conventional high vaginal
swab (HVS) and a rectal swab were taken from
each woman, together with a 10 ml vaginal
washing using sterile water. The women were
treated with a single 500 mg clotrimazole pes-
sary and asked to re-attend 1, 4, and 12 weeks
after treatment, or if their symptoms recurred.
The women were asked about symptoms, signs
were recorded, and HVS and vaginal washings
were repeated at each visit.
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SAMPLE COLLECTION AND PROCESSING
Conventional HVS and rectal swabs were
collected and plated onto Sabouraud agar,
before incubation at 37°C for 48 hours. Vaginal
washings were collected by introducing 10 ml
of sterile water into the vagina using a quill
attached to a syringe. The washings were then
re-aspirated into the syringe and transferred to
a sterile Universal container. Each sample was
serially diluted so that the number of viable
colonies could subsequently be quantified. The
neat washings and each dilution (0.1 ml
volumes) were plated onto Sabouraud agar and
incubated at 37°C for 48 hours. The number of
colonies that grew was recorded and the results
expressed as colony forming units (CFU) per
ml of wash fluid.
Rectal and vaginal isolates were identified as
Candida albicans on the basis of the germ tube
test15 and the production of chlamydospores on
Czapek Dox medium. Germ tube negative iso-
lates were further identified using Auxocolor
kits (Sanofi Pasteur, France). Five yeast
colonies from each positive vaginal or rectal
specimen were preserved using the Protect sys-
tem (Technical Services Ltd, Heywood, UK)
and kept at −70°C.
TYPING OF CANDIDA ISOLATES
DNA extraction
The method was adapted from Scherer and
Stevens.16 Five yeast colonies from the vaginal
washings and five yeast colonies from the rectal
swab taken at the initial visit were inoculated
onto separate Sabouraud agar plates and incu-
bated for 48 hours. Five yeast colonies from
vaginal washings were similarly cultured from
each subsequent visit, if positive cultures were
obtained. DNA was then extracted from each
of these isolates.
Digestion and electrophoresis of DNA
The extracted DNA was digested using a spe-
cific restriction enzyme (EcoRI). The samples
were then subjected to gel electrophoresis to
separate the fragments into specific bands
according to size.
Southern blotting and hybridisation
The electrophoresed DNA was blotted from
the gel onto a nylon membrane, according to
the method of Southern16 and identified by
hybridisation with a Ca3 probe.17
ANTIFUNGAL SUSCEPTIBILITY TESTING
Antifungal susceptibility testing was performed
by the broth microdilution method according
to the National Committee for Clinical Labo-
ratory Standards M27-A method.18 The anti-
fungal agents used were clotrimazole (CTZ;
Sigma) and fluconazole (FCZ; kindly provided
by Pfizer, UK). The antifungal agents were
tested at concentrations ranging from 64–
0.125 mg/l. The minimum inhibitory concen-
tration (MIC) was assessed visually and
defined as the concentration of antifungal that
resulted in an 80% inhibition of growth of the
test strain. For fluconazole, isolates with MICs
less than or equal to 8 mg/l were defined as
“sensitive,” 16–32 mg/l as “susceptible de-
pendent on dose,” and 64 mg/l or greater as
“resistant.” For clotrimazole, isolates with
MICs less than or equal to 1 mg/l were defined
as sensitive, 2–8 mg/l as susceptible dependent
on dose, and 16 mg/l or greater as resistant.
DATA ANALYSIS
The questionnaires were analysed using SPSS
for Windows. Associations of Candida culture
results with signs and symptoms were identi-
fied by bivariate analysis using the ÷2 test, Pear-
son coeYcient, and the p value calculated. Gels
were analysed using the method of Schmid et
al19 for DNA fingerprinting, calculation of
similarity coeYcient (SAB), and histogram and
dendrogram genesis. Ca3 hybridisation pat-
terns of five colonies per isolate were analysed
for band position only in the size range of
2.25–19 kb and the results stored in the
Dendron database. This constructs histograms
and dendrograms by the unweighted pair
group method. SABs were recorded for each pair
of strains from the linear list of the matrix coef-
ficient, rather than branching points, as it is
more accurate. In this study, the cut-oV points
for strain relatedness were lowered compared
to other studies using this probe, as the band
intensity was not included in the analysis, and
because Dendron analysis only involved bands
lower than 7.9 kb. Genetically identical isolates
were defined to have SABs > 0.96, genetically
similar but not identical isolates had SABs in the
range 0.96–0.85, and genetically unrelated iso-
lates had SABs < 0.85.
Results
STUDY POPULATION
A total of 121 women were recruited to the
study. The women had a mean age of 26 years
(range 19–53 years). All had symptoms and
signs suggestive of VVC, but only 78 of them
(65%) had positive Candida cultures at the ini-
tial visit. Table 1 shows the relation between
symptoms and culture results in the study
population at the initial visit.
MICROBIOLOGY RESULTS AT THE INITIAL VISIT
Of the 78 women who had culture positive
vaginal washings, C albicans was isolated from
75, C glabrata from two, and C tropicalis from
one. Rectal swabs were positive for Candida in
80 women, of whom 67 had concomitant initial
positive vaginal washings. Again,C albicans was
the commonest species isolated from rectal
swabs (n=78), followed by C glabrata (n=1)
and Saccharomyces cerevisiae (n=1). The patient
with C glabrata isolated from the rectal swab
Table 1 Relation between symptoms and culture results in 121 women at their initial visit
Variable
Total n=121
(%)
Culture positive
n=78 (%)
Culture negative
n=43 (%) p Value
History
OCP 53 (43.8) 30 (56.6) 23 (43.4) 0.16 (NS)
HSE 86 (71.1) 58 (67.4) 35 (40.7)
Symptoms
Itching 97 (80.2) 68 (70.1) 29 (29.9) 0.009
Soreness 78 (64.5) 56 (71.8) 22 (28.2) 0.023
Discharge 78 (64.5) 50 (64.1) 28 (35.9) 1.0 (NS)
Dysuria 6 (5.0) 3 (50.0) 3 (50.0) 0.747 (NS)
Dyspareunia 2 (1.6) 1 (50.0) 1 (50.0) 0.667 (NS)
OCP = oral contraceptive pill.
HSE = history of similar episodes.
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also had C glabrata in the vaginal washings.
One patient with vaginal C glabrata and one
with vaginal C tropicalis both had negative rec-
tal cultures. The woman with the S cerevisiae in
the rectal swab had a negative vaginal culture.
The results for the HVS were broadly
similar, with 72 of the 78 women with positive
washings also having a positive HVS. In most
cases, the results from the washings and HVS
from the same woman were identical, but there
were five women with positive washings and
negative HVS and one woman with a positive
HVS and negative washings.
CLINICAL OUTCOME
Of the 78 women who had positive vaginal
washings at the initial visit, a total of 47 women
completed the clinical study (either returned for
four scheduled visits or experienced clinical
recurrence) within the 3 month study period.
These 47 women were classified into three
groups according to their clinical outcome (fig
1):
+ Thirteen women had an initial positive vagi-
nal washing, but became and remained cul-
ture negative after therapy (one-oV posi-
tives)
+ Twelve women were culture positive at visit
2 despite therapy (persistent carriage)
+ Twenty two women who were initially
culture positive, became culture negative
after therapy but again became culture posi-
tive, within the 12 week period (recurrent
infection).
Of the 12 women with persistent carriage at
1 week post-treatment, nine were asympto-
matic. Six of these nine women had a negative
HVS, but positive vaginal washings on culture.
Seven of the nine women continued to attend
for follow up and seven subsequently devel-
oped symptoms requiring treatment.
VIABLE CANDIDA COUNTS AND RESPONSE TO
TREATMENT
Viable Candida counts in vaginal washings
taken at the initial visit were not predictive of
clinical outcome. However, women with
asymptomatic persistent infection had signifi-
cantly lower viable Candida counts at visit 2
compared with visit 1 (p<0.05). In women with
symptomatic persistent infection there was no
significant diVerence between the counts at
visits 1 and 2 (see table 2).
GENETIC RELATEDNESS BETWEEN VAGINAL AND
RECTAL ISOLATES (PRETREATMENT)
Of the 66 women with positive cultures for C
albicans in both vagina and rectum, 52 had
genetically identical isolates. In eight women
the isolates were highly similar and in six they
were unrelated.
GENETIC RELATEDNESS OF VAGINAL ISOLATES
PRETREATMENT AND POST-TREATMENT
In women with recurrent infection, SAB scores
between primary and subsequent vaginal
isolates ranged from 1.00 to 0.52. In 17 of the
22 women in the recurrent group, strain main-
tenance was seen, with 14 women having iden-
tical strains and three having highly similar
strains. In the five remaining women, four had
strain replacement and in one woman the Can-
dida species changed from C albicans to C gla-
brata.
In the persistent carriage group, nine women
had strain maintenance, two women had strain
replacement, and in one patient the species of
Candida isolated changed from C albicans to C
parapsilosis. Figure 2 shows the Ca3 Southern
blot hybridisation patterns of the Candida
isolates from a patient who was culture positive
at the initial visit as well as on the two
subsequent visits (persistent carriage group).
The blot demonstrates that strain maintenance
was seen in this patient. Figure 3 shows the
hybridisation patterns of isolates from two
patients with recurrent infection; one illustrates
strain maintenance and the other strain re-
placement.
ANTIFUNGAL SUSCEPTIBILITY TESTING
None of the isolates from the women in this
study was resistant to fluconazole or clotrima-
zole (MIC ranges: 0.125–32 mg/l and 0.125–2
mg/l respectively). One post-treatment C albi-
cans isolate from a woman in the persistent
group, was susceptible dependent on dose to
fluconazole. Eight C albicans isolates also
Figure 1 Classification of women in the study according to Candida culture results.
Cohort of 121
women enrolled in
study
Culture
negative
(n = 43)
Culture
positive
(n = 78)
Culture
negative
Culture
positive
Culture
negative
Culture
positive
Culture
negative
Visit 4
Visit 3
Visit 2
Visit 1
Culture
positive
Recurrent infection
(n = 22)
Persistent
carriage
(n = 12)
One-off
positives
(n = 13)
Table 2 Mean log10 viable count of Candida in women with persistent symptomatic or
asymptomatic infection
Mean log10 viable Candida count
(95% confidence limits)
p ValueVisit 1 Visit 2
Persistent carriage (n=12)
Asymptomatic (n=9) 4.38 (0.59) 2.18 (0.98) <0.05
Symptomatic (n=3) 4.31 (1.94) 3.06 (0.44) NS
Data analysed by ANOVA.
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showed susceptibility dependent on dose to
clotrimazole, three of which came from the
same patient in the persistent carriage group.
Discussion
In this study, 121 women presented with
symptoms suggesting acute vulvo-vaginal can-
didosis (VVC), yet only two thirds of them
were culture positive for Candida species.
Vulval itching and soreness were the only
symptoms predictive of a culture positive vagi-
nal washing, but overall, symptoms were
non-specific, confirming the findings of previ-
ous published studies that diagnosis on the
basis of history alone is unreliable.20
Hopwood et al21 found a positive relation
between viable yeast counts and symptoms and
signs of VVC. We wondered whether viable
Candida counts in vaginal washings taken at
the initial visit would be predictive of the clini-
cal outcome, but our results showed no associ-
ation. However, in women with persistent
infection after initial treatment, those who had
higher viable Candida counts were more likely
to be symptomatic.
C albicans was by far the commonest isolate
from both vagina and rectum (96% of vaginal
isolates and 98% of rectal isolates). These
results are consistent with our previous obser-
vation22 that there has been no increase in the
incidence of non-albicans strains among
women attending the genitourinary medicine
clinic in Leeds since the introduction of “over
the counter” antifungals.
Work in vitro has shown that the sensitivity
of swabs as a sampling method for yeasts is
low.3 In the laboratory, swabs will only yield
positive cultures if they have been placed in a
suspension containing at least 103 viable
organisms per ml. This study highlighted the
discrepancy between culture results from HVS
and vaginal washings. Of the 12 women with
persistent carriage of yeast 1 week after
treatment, half were culture negative by HVS,
but positive by vaginal washings. Nine of the 12
women with persistent carriage in this study
were asymptomatic; seven of them continued
to attend and subsequently developed symp-
toms requiring re-treatment. Thus, in clinical
practice some women treated for “recurrent
infection” on the basis of HVS results may in
fact have incomplete eradication of yeasts after
treatment and should therefore be classed as
persistent carriers.
The analysis of the genetic relatedness of
vaginal isolates pretreatment and post-
treatment demonstrated genotypic strain main-
tenance in the majority of women (77% of
women in the recurrent group and 75% of
those in the persistent carriage group). There
have been a number of other studies that have
confirmed the genetic similarity of Candida
species isolated during recurrent episodes of
VVC (RVVC).13 14 23 However, these studies
only examined isolates obtained during symp-
tomatic recurrence. Only a few studies have
included specimens taken between sympto-
matic episodes, and have included very small
numbers of patients. For example, Stein et al24
studied four women with RVVC, taking
samples 1, 7, and 30 days after the treatment.
Three had symptomatic recurrences with the
same strain of C albicans as was initially isolated
from the vagina. Soll et al25 took repeated sam-
ples from various body sites in a single patient
and found that strain maintenance occurred
during three episodes of vaginal infection. A
study examining chemoprophylaxis in women
Figure 2 Ca3 hybridisation patterns of isolates from a woman in the persistent carriage
group. Lanes 1–5 represent vaginal isolates taken at visit 1 and lanes 6–10 represent rectal
isolates from visit 1. Lanes 11–15 represent vaginal isolates obtained at visit 2 when the
patient was asymptomatic. Ten weeks after her initial visit, the patient again developed
symptoms. Lanes 16–20 represent vaginal isolates obtained at this time. Strain
maintenance occurred throughout with only minor variations in band pattern.
kb
C 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20
7.9
5.4
3.3
–
–
–
Figure 3 Southern blot hybridisation pattern of isolates
from two women in the recurrent positive group.Lane C is a
reference Candida albicans isolate. Lanes 1–3 illustrate strain
maintenance in one patient. Lanes 1 and 2 represent the
vaginal and rectal isolates respectively, obtained at the initial
visit. Lane 3 represents the vaginal isolate obtained during
the recurrent episode. Lanes 4–6 illustrate strain replacement
in another woman.Lanes 4 and 5 represent vaginal and
rectal isolates obtained initially. Lane 6 represents the vaginal
isolate obtained during the recurrent episode.
kb
C 1 2 3 4 5 6
7.9
5.4
3.3
–
–
–
182 El-Din, Reynolds, Ashbee, et al
www.sextransinf.com
with RVVC included a larger number of
women and vaginal samples were also taken
between symptomatic recurrences.4 In this
study, nearly half the women had strain
replacement or a change of Candida species at
the first symptomatic recurrence. However, as
all the patients were receiving ketoconazole
prophylaxis, this may have exerted a selective
pressure encouraging the emergence of diVer-
ent strains or species of Candida.
In summary, our findings support the “vagi-
nal relapse” hypothesis in women with RVVC
and have important implications for the
treatment of women with recurrent symptoms.
We chose a single clotrimazole pessary (500
mg) as treatment because this is the cheapest
antifungal treatment available over the counter
and is also frequently prescribed by general
practitioners. Despite widespread usage of
antifungal drugs, we and others have found no
evidence of resistance to either fluconazole or
clotrimazole in immunocompetent patients
with recurrent infection or persistent carriage
of Candida.22 26 27 As antifungal resistance does
not seem to be a problem in the general popu-
lation, it may be appropriate to use more
prolonged courses of antifungal treatment in
women with RVVC in order to increase the
chances of complete eradication of yeasts. One
possible approach is an extended course of oral
antifungals initially followed by regular prophy-
laxis, say once or twice monthly, with either
vaginal pessaries or systemic therapy.
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